Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer Acquires Icagen | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pfizer Acquires Icagen

$56 mil. acquisition locks in ion channel development partner

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer will acquire Icagen, Inc., one of its development and commercialization partners. The acquisition will cost $56 million for the 89% of Icagen shares that Pfizer does not currently own.

In 2007, Pfizer and Icagen entered into a discovery and commercialization collaboration for the development of treatments for pain and related disorders utilizing sodium ion channels, which have the potential for fewer side effects.

“We’re excited that Icagen, a global leader in pain research, will join Pfizer, further strengthening our innovative core,” said Ruth McKernan, senior vice president, Pfizer’s Pain & Sensory Disorders and Regenerative Medicine unit, known as Neusentis. “Icagen’s capabilities and core ion channel technology will help to further expand Pfizer’s position in the pain relief disease area and our ability to develop potential first-in-industry drugs for the treatment of pain and related disorders.”

“By joining forces in a more integrated manner, we believe that our joint efforts towards the identification and development of novel pharmaceuticals targeting specific ion channels will be significantly enhanced,” said P. Kay Wagoner, Ph.D., chief executive officer of Icagen.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics